The therapeutic potential of cellular vaccines that contain antigen-loaded CD1c (BDCA-1)+ myDCs, also in combination with pDCs, has already been under investigation in early clinical trials in patients with metastatic melanoma or prostate cancer indicating objective tumor responses and immunogenicity [31,32,33]. Here, CD1C is linked to neoplasm.